Quarterly report pursuant to Section 13 or 15(d)

Revenue (Tables)

v3.20.2
Revenue (Tables)
 6 Months Ended
Jun. 30, 2020
Revenue from Contract with Customer [Abstract]  
Schedule of Recognized Revenues
During the three and six months ended June 30, 2020 and 2019, respectively, the Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):
  Three Months Ended June 30, Six Months Ended June 30,
  2020 2019 2020 2019
Seattle Genetics $ 8,512    $ 504    $ 8,960    $ 1,429   
AstraZeneca 2,334    3,888    5,045    9,908   
Servier 400    940    10,502    2,540   
Total Revenue $ 11,246    $ 5,332    $ 24,507    $ 13,877   
Schedule of Potential Milestone Payments
Under the Company´s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions):
  Research, Development, Regulatory & Commercial Milestones Sales Milestones
AstraZeneca $ 1,111    $ 960   
Servier 682    605   
Seattle Genetics 764    450   
Total potential milestone payments $ 2,557    $ 2,015